FY2027 EPS Estimates for REGENXBIO Lifted by Leerink Partnrs

REGENXBIO Inc. (NASDAQ:RGNX) – Investment analysts at Leerink Partnrs upped their FY2027 earnings per share (EPS) estimates for shares of REGENXBIO in a report issued on Monday, November 18th. Leerink Partnrs analyst M. Foroohar now expects that the biotechnology company will earn ($1.25) per share for the year, up from their previous forecast of ($1.87). The consensus estimate for REGENXBIO’s current full-year earnings is ($4.84) per share. Leerink Partnrs also issued estimates for REGENXBIO’s FY2028 earnings at $1.10 EPS.

RGNX has been the subject of a number of other research reports. StockNews.com upgraded REGENXBIO from a “sell” rating to a “hold” rating in a research note on Friday, September 20th. HC Wainwright cut their price target on REGENXBIO from $40.00 to $36.00 and set a “buy” rating for the company in a research note on Thursday. Barclays cut their price target on REGENXBIO from $55.00 to $50.00 and set an “overweight” rating for the company in a research note on Monday, August 5th. Morgan Stanley reiterated an “overweight” rating and issued a $22.00 price target on shares of REGENXBIO in a research note on Friday, November 15th. Finally, Chardan Capital reiterated a “buy” rating and issued a $52.00 price target on shares of REGENXBIO in a research note on Wednesday. Two research analysts have rated the stock with a hold rating and eleven have assigned a buy rating to the company. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and an average price target of $35.27.

REGENXBIO Price Performance

NASDAQ RGNX opened at $9.18 on Thursday. REGENXBIO has a 1-year low of $8.53 and a 1-year high of $28.80. The business’s fifty day moving average price is $10.37 and its 200-day moving average price is $12.14. The stock has a market capitalization of $454.82 million, a price-to-earnings ratio of -1.83 and a beta of 1.23.

Institutional Trading of REGENXBIO

Several institutional investors have recently added to or reduced their stakes in RGNX. Janney Montgomery Scott LLC bought a new stake in shares of REGENXBIO during the first quarter valued at approximately $304,000. Swiss National Bank raised its stake in shares of REGENXBIO by 4.5% during the first quarter. Swiss National Bank now owns 81,500 shares of the biotechnology company’s stock valued at $1,717,000 after acquiring an additional 3,500 shares in the last quarter. ProShare Advisors LLC raised its stake in shares of REGENXBIO by 8.3% during the first quarter. ProShare Advisors LLC now owns 11,384 shares of the biotechnology company’s stock valued at $240,000 after acquiring an additional 874 shares in the last quarter. State Board of Administration of Florida Retirement System raised its stake in shares of REGENXBIO by 33.3% during the first quarter. State Board of Administration of Florida Retirement System now owns 15,485 shares of the biotechnology company’s stock valued at $326,000 after acquiring an additional 3,870 shares in the last quarter. Finally, Vanguard Group Inc. raised its stake in shares of REGENXBIO by 9.8% during the first quarter. Vanguard Group Inc. now owns 4,876,881 shares of the biotechnology company’s stock valued at $102,756,000 after acquiring an additional 436,043 shares in the last quarter. Institutional investors own 88.08% of the company’s stock.

Insiders Place Their Bets

In other REGENXBIO news, Director Argeris N. Karabelas sold 10,000 shares of the firm’s stock in a transaction dated Tuesday, October 1st. The shares were sold at an average price of $10.11, for a total value of $101,100.00. Following the completion of the sale, the director now owns 11,286 shares of the company’s stock, valued at $114,101.46. This trade represents a 46.98 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. 13.13% of the stock is owned by insiders.

About REGENXBIO

REGENXBIO Inc, a clinical-stage biotechnology company, provides gene therapies that deliver functional genes to cells with genetic defects in the United States. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. The company’s products in pipeline includes ABBV-RGX-314 for the treatment of wet age-related macular degeneration, diabetic retinopathy, and other chronic retinal diseases; and RGX-202, which is in Phase I/II clinical trial for the treatment of Duchenne muscular dystrophy.